Abstract

BackgroundMultidrug-resistant Pseudomonas aeruginosa is a serious challenge for antimicrobial therapy of nosocomial infections, as it possesses several mechanisms of antimicrobial resistance. In Central Greece, a sudden increase of infections caused by carbapenem-resistant P. aeruginosa was observed during 2011, indicating the need for further analysis.MethodsFive-hundred and sixty-eight P. aeruginosa isolates were collected consecutively during an 8-month period in 2011 from inpatients treated in three hospitals in the Thessaly region (1,000,000 habitants) of Greece. Carbapenem-resistant P. aeruginosa (n = 284) were characterized by antimicrobial susceptibility testing and β-lactamase content, and the genetic relatedness of carbapenemase-producing isolates was assessed by BOX-PCR, multilocus sequence typing, and eBURST analysis. Mapping of the class I integrons of Verona integron-encoded metallo-β-lactamase (VIM)-carrying isolates was also performed, and clinical data of the VIM producers were reviewed.ResultsEighty (14.1%) out of the 568 P. aeruginosa isolates recovered from clinical specimens were VIM producers. Multilocus sequence typing revealed high prevalence of the international clones ST111 and ST235 among blaVIM-2- and blaVIM-4-positive isolates, respectively. blaVIM-17 was identified in an isolate of a novel sequence type (ST1457). blaVIM gene cassettes were carried by five distinct class I integrons, including two novel ones.ConclusionsSince the first report of VIM-producing P. aeruginosa in 2000, this microorganism still remains among the most prevalent multidrug resistant pathogens in Greece. The spread of VIM-producers belonging to the most common international clones (ST111 and ST235), the spread of integrons of divergent structures, and the emergence of novel integrons underscore their ongoing evolution.

Highlights

  • Multidrug-resistant Pseudomonas aeruginosa is a serious challenge for antimicrobial therapy of nosocomial infections, as it possesses several mechanisms of antimicrobial resistance

  • Of the 284 carbapenem-resistant isolates, 80 (28%) isolates were positive for carbapenemase production by phenotypic screening and were positive for blaVIM by polymerase chain reaction (PCR)

  • The remaining 204 carbapenem-resistant P. aeruginosa isolates were negative for carbapenemase production by phenotypic screening and negative for all Extended-spectrum β-lactamase (ESBL) and carbapenemase genes tested

Read more

Summary

Introduction

Multidrug-resistant Pseudomonas aeruginosa is a serious challenge for antimicrobial therapy of nosocomial infections, as it possesses several mechanisms of antimicrobial resistance. P. aeruginosa is a leading cause of nosocomial infections, especially in immunocompromised patients. The high prevalence of multidrug-resistant (MDR) P. aeruginosa is a serious challenge for antimicrobial therapy. MDR P. aeruginosa possesses several mechanisms of antimicrobial resistance; over-expression of the intrinsic AmpC-type cephalosporinase, which confers resistance. Acquired resistance to β-lactams is often reported in P. aeruginosa as a result of the acquisition of extended spectrum β-lactamases (ESBLs), such as the PER-1, VEB-1, TEM, and SHV type ESBLs [2]. Nosocomial outbreaks caused by MBL-producing P. aeruginosa have been reported in several countries worldwide [6,7,8,9,10]. Implementation of multilocus sequence typing (MLST) has facilitated the elucidation of the global epidemiology and evolution of these multidrug-resistant pathogens [11,12,13,14]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call